Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	25.28B
Revenue (ttm)	1.57B
Net Income (ttm)	568.30M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	44.48
Forward PE	39.89
Dividend	0.04 (0.99%)
Ex-Dividend Date	Sep 22, 2025

Volume	4,063
Average Volume	1,478
Open	4.040
Previous Close	4.040
Day's Range	4.040 - 4.120
52-Week Range	1.970 - 4.420
Beta	n/a
RSI	58.68
Earnings Date	Nov 18, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY